MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy.

ABSTRACT:

Background

Elevated uptake of the [¹⁸ F]AV-1451 tau-PET ligand has been observed cross-sectionally in subjects with progressive supranuclear palsy (PSP). However, it is unknown how the ligand performs longitudinally in PSP. We aimed to determine how regional measures of change on [¹⁸ F]AV-1451 PET perform as longitudinal biomarkers of PSP compared with the more established biomarker of rate of midbrain atrophy.

Methods

Sixteen subjects with PSP underwent 2 serial [¹⁸ F]AV-1451 tau-PET scans and 3-Tesla MRI over 12 months and were age- and sex-matched to 39 healthy controls with longitudinal [¹⁸ F]AV-1451 PET. Median [¹⁸ F]AV-1451 uptake was calculated for each scan for regions of interest across the brain and divided by

SUBMITTER: Whitwell JL 

PROVIDER: S-EPMC6361527 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature